Skip to main content
. 2021 Jun 18;9(6):670. doi: 10.3390/vaccines9060670

Figure 1.

Figure 1

Antigens used in preclinical or clinical trials for development of either active, passive or in combination, vaccines against Bcc or P. aeruginosa infections.